Connexins in cancer: bridging the gap to the clinic

Aasen, T., Leithe, E., Graham, S. V. , Kameritsch, P., Mayán, M. D., Mesnil, M., Pogoda, K. and Tabernero, A. (2019) Connexins in cancer: bridging the gap to the clinic. Oncogene, 38(23), pp. 4429-4451. (doi: 10.1038/s41388-019-0741-6) (PMID:30814684) (PMCID:PMC6555763)

178938.pdf - Published Version
Available under License Creative Commons Attribution.



Gap junctions comprise arrays of intercellular channels formed by connexin proteins and provide for the direct communication between adjacent cells. This type of intercellular communication permits the coordination of cellular activities and plays key roles in the control of cell growth and differentiation and in the maintenance of tissue homoeostasis. After more than 50 years, deciphering the links among connexins, gap junctions and cancer, researchers are now beginning to translate this knowledge to the clinic. The emergence of new strategies for connexin targeting, combined with an improved understanding of the molecular bases underlying the dysregulation of connexins during cancer development, offers novel opportunities for clinical applications. However, different connexin isoforms have diverse channel-dependent and -independent functions that are tissue and stage specific. This can elicit both pro- and anti-tumorigenic effects that engender significant challenges in the path towards personalised medicine. Here, we review the current understanding of the role of connexins and gap junctions in cancer, with particular focus on the recent progress made in determining their prognostic and therapeutic potential.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Graham, Professor Sheila
Authors: Aasen, T., Leithe, E., Graham, S. V., Kameritsch, P., Mayán, M. D., Mesnil, M., Pogoda, K., and Tabernero, A.
College/School:College of Medical Veterinary and Life Sciences > Institute of Infection Immunity and Inflammation
Journal Name:Oncogene
Publisher:Springer Nature
ISSN (Online):1476-5594
Published Online:27 February 2019
Copyright Holders:Copyright © 2019 The Authors
First Published:First published in Oncogene 38(23): 4429-4451
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
438191The role of the hD1g, ZO-1 and hScrib tumour suppressors in control of Cx43 gap junctional intercellular communication in HPV-associated tumourigenesis.Sheila GrahamWorldwide Cancer Research (WWCANRES)08-0159MVLS III - CENTRE FOR VIRUS RESEARCH